In November 2023, the UK's Medicines and Healthcare products Regulatory Agency authorized a therapy that edits a patient's own DNA to treat the root cause of sickle cell disease. It was the first time any regulator had approved a CRISPR-based medicine. One month later, the FDA followed. By February 2024, so had the European Commission.
That therapy is Casgevy. It is no longer experimental, no longer confined to clinical trials. It is a commercial product with a list price, a manufacturing supply chain, and a growing list of treated patients. The first person to receive Casgevy outside a trial was treated in 2024. By 2026, the question has shifted from "Will CRISPR medicine work?" to "Who can actually get it?"
This article compares the two approved gene therapies for sickle cell disease—Casgevy and Lyfgenia—head to head. It also examines what's coming next: in vivo CRISPR therapies that edit cells directly inside the body, bypassing the grueling extraction-and-reinfusion process entirely. If you want to understand where gene editing stands in 2026, what it costs, and what it can and cannot do, this is the current picture.
Key Takeaway: As of early 2026, exactly one CRISPR/Cas9 gene-edited therapy has received regulatory approval worldwide: Casgevy. All approved CRISPR therapies are ex vivo—cells are removed, edited in a lab, and reinfused. No in vivo CRISPR therapy has been approved yet.
The path from a lab discovery to an approved medicine took just over a decade.
2012: Jennifer Doudna and Emmanuelle Charpentier published their landmark paper showing that CRISPR/Cas9 could be programmed to cut specific DNA sequences. The implications for medicine were immediate and obvious, though the engineering challenges were enormous.
2020: Doudna and Charpentier received the Nobel Prize in Chemistry. By then, CRISPR was already in human clinical trials for sickle cell disease and beta-thalassemia.
2023: The UK MHRA authorized Casgevy in November. The FDA approved it in December. Both decisions came after clinical trials showed that most patients treated with the therapy stopped experiencing the severe pain crises that define sickle cell disease.
2024: The first commercial patients were treated. CRISPR Therapeutics and Vertex Pharmaceuticals, the companies behind Casgevy, began scaling up manufacturing. Bluebird bio's Lyfgenia—a different type of gene therapy for sickle cell disease—also reached the market.
2025–2026: The focus shifted to in vivo editing. Intellia Therapeutics reported positive Phase 3 results for NTLA-2002, an in vivo CRISPR therapy for hereditary angioedema. If approved, it would be the first CRISPR medicine that doesn't require removing cells from the body.
Key Takeaway: The first CRISPR therapy went from Nobel Prize to regulatory approval in three years. The next wave—in vivo therapies—could reach the market by 2027 or 2028.
Casgevy is a CRISPR/Cas9-edited autologous hematopoietic stem cell therapy. In plain terms: doctors collect a patient's blood-forming stem cells, edit them in a laboratory, and give them back. The editing disables a genetic switch called the BCL11A enhancer. That switch normally suppresses fetal hemoglobin after birth. By turning it off, the body resumes producing fetal hemoglobin—a form of hemoglobin that doesn't sickle.
The clinical data are striking. In trials, 97% of sickle cell patients treated with Casgevy were free of severe vaso-occlusive crises for at least 12 consecutive months. For beta-thalassemia, 93% of patients achieved transfusion independence for at least 12 consecutive months. These aren't marginal improvements. They represent a functional cure for most patients who receive the therapy.
The process is demanding:
The US list price is $2.2 million per patient. That figure doesn't include hospitalization, conditioning chemotherapy, or post-treatment care. Fewer than 100 treatment centers worldwide are authorized to administer Casgevy. Manufacturing capacity is limited, and the wait time from collection to reinfusion can stretch to several months.
Key Takeaway: Casgevy is a functional cure for most sickle cell and beta-thalassemia patients who receive it, but the treatment itself—particularly the chemotherapy conditioning—carries serious risks.
Lyfgenia, developed by bluebird bio, is also approved for sickle cell disease. But it works differently.
Instead of editing the genome with CRISPR, Lyfgenia uses a lentiviral vector to deliver a modified beta-globin gene into the patient's stem cells. The goal is similar—increase healthy hemoglobin and reduce sickling—but the mechanism is gene addition, not gene editing.
Lyfgenia also reduces vaso-occlusive crises in most patients. The safety profile differs: because lentiviral vectors insert genetic material into the genome somewhat randomly, there's a theoretical risk of insertional mutagenesis—the vector landing in a spot that disrupts a tumor suppressor gene or activates an oncogene. This risk is considered low but not zero, and it's the primary reason Lyfgenia carries a boxed warning for hematologic malignancy.
Lyfgenia's US list price is $3.1 million, higher than Casgevy's $2.2 million.
| Feature | Casgevy | Lyfgenia |
|---|---|---|
| Mechanism | CRISPR/Cas9 editing of BCL11A enhancer | Lentiviral gene addition of modified beta-globin |
| Approach | Gene editing (disabling a switch) | Gene therapy (adding a gene) |
| Approved for | Sickle cell disease, beta-thalassemia | Sickle cell disease |
| List price (US) | $2.2 million | $3.1 million |
| Boxed warning | None | Hematologic malignancy |
Key Takeaway: Lyfgenia is a viable alternative for sickle cell patients, but it uses older gene therapy technology and carries a boxed warning for blood cancers. Casgevy's CRISPR approach avoids insertional mutagenesis but introduces off-target editing risk.
Casgevy edits the genome. Lyfgenia adds to it. This is the fundamental distinction. CRISPR editing is more precise—it targets a specific sequence and makes a defined cut. Lentiviral gene addition is less precise but has a longer track record in gene therapy.
Casgevy is approved for both sickle cell disease and transfusion-dependent beta-thalassemia. Lyfgenia is approved only for sickle cell disease.
Both therapies produce high rates of crisis reduction. Direct comparisons are difficult because the trials used different endpoints and patient populations. Neither has been tested head-to-head against the other.
Casgevy's primary risk is off-target editing, which has not been observed as a clinical problem in treated patients so far but remains a theoretical concern requiring long-term monitoring. Lyfgenia's primary risk is insertional mutagenesis, which has been observed in other lentiviral gene therapy contexts and is serious enough to warrant a boxed warning.
Both are ex vivo therapies. Both require stem cell collection, myeloablative conditioning, and reinfusion. The patient experience is similar. The logistical burden is similar.
Casgevy is $900,000 cheaper at list price. Both are among the most expensive medicines ever approved.
Both face the same bottlenecks: limited manufacturing capacity, few qualified treatment centers, and insurance hurdles. Neither is widely available outside high-income countries.
For sickle cell disease: Casgevy has a better safety profile on paper—no boxed warning, no insertional mutagenesis risk—and a lower price. Lyfgenia remains a reasonable option if Casgevy is unavailable or if a patient has a contraindication.
For beta-thalassemia: Casgevy is the only approved CRISPR option. Lyfgenia is not approved for this indication.
For patients who want the most established technology: Lyfgenia builds on decades of lentiviral gene therapy research. Some clinicians may prefer it for that reason.
Key Takeaway: Casgevy is the better first choice for most eligible patients due to lower cost and no boxed warning. Lyfgenia is a viable alternative when Casgevy isn't accessible.
The biggest limitation of Casgevy and Lyfgenia is that they're ex vivo. Cells must be removed, edited, and returned. That means chemotherapy conditioning, weeks of hospitalization, and a manufacturing process that can take months.
In vivo editing bypasses all of that. The therapy is injected directly into the patient, and the editing happens inside the body.
The most advanced in vivo CRISPR therapy is Intellia Therapeutics' NTLA-2002 for hereditary angioedema, a rare genetic disorder causing severe swelling attacks. In a Phase 2 trial, the therapy reduced attacks by 95%. Intellia has reported positive Phase 3 results. If approved, NTLA-2002 would be the first in vivo CRISPR medicine.
If NTLA-2002's Phase 3 results hold, approval could come in 2027. Other in vivo therapies are likely to follow within two to three years.
Key Takeaway: In vivo CRISPR editing could eliminate the most burdensome aspects of current therapies—but no in vivo CRISPR therapy is approved as of early 2026.
The science has moved faster than the infrastructure.
Casgevy costs $2.2 million. Lyfgenia costs $3.1 million. These prices reflect the complexity of manufacturing a personalized cell therapy, but they also reflect a market where companies set prices based on what insurers will pay, not what the therapy costs to produce.
Both therapies require specialized manufacturing facilities. Each batch is patient-specific. There's no economies-of-scale advantage. CRISPR Therapeutics and Vertex are expanding capacity, but the timeline for meaningful improvement is measured in years.
Fewer than 100 centers worldwide are authorized to administer Casgevy. Most are in the US and Europe. Patients in low- and middle-income countries—where sickle cell disease is most common—have essentially no access.
An estimated 20,000 people in the US have severe sickle cell disease that would qualify them for Casgevy. As of early 2026, only a fraction have been treated. The gap between eligibility and access is enormous.
Key Takeaway: The biggest barrier to CRISPR medicine in 2026 isn't science. It's money, manufacturing, and geography.
CRISPR can cut DNA at sites other than the intended target. In Casgevy trials, off-target editing has not been linked to any clinical harm. But the FDA requires 15 years of follow-up for a reason: some risks take years or decades to appear.
Myeloablative chemotherapy is the most dangerous part of the treatment. It can cause infertility, organ damage, and secondary cancers. For some patients, the risks of conditioning may outweigh the benefits of the therapy itself.
Data so far show that the edited cells persist and continue producing fetal hemoglobin. Patients treated in early trials remain free of crises years later. But "years" is not "decades."
No approved therapy edits germline cells. All current CRISPR medicines edit somatic cells—the edits are not inherited. Regulatory agencies have made clear that germline editing for reproductive purposes is not approved and remains ethically fraught.
Key Takeaway: Long-term safety data are still accumulating. The 15-year follow-up requirement reflects genuine uncertainty about delayed effects.
A genuine breakthrough. The first approved CRISPR therapy, with efficacy that approaches a cure for sickle cell disease and beta-thalassemia. Its limitations are practical, not scientific: cost, access, and the burden of ex vivo treatment.
A viable alternative for sickle cell disease. It uses older technology and carries a boxed warning, but it works. For patients who can't access Casgevy, it's a reasonable second option.
In vivo editing is the next frontier. If Intellia's NTLA-2002 is approved, it will mark the beginning of a new phase: CRISPR therapies that are simpler, cheaper, and scalable. That won't happen overnight. But the direction is clear.
Key Takeaway: CRISPR medicine has arrived. It works. The challenge now is making it available to the people who need it.
What CRISPR therapies are approved as of 2026? Only one: Casgevy, approved for sickle cell disease and transfusion-dependent beta-thalassemia. Lyfgenia is a gene therapy but not a CRISPR therapy.
How does Casgevy work? It edits the BCL11A enhancer in a patient's stem cells, causing the body to produce fetal hemoglobin instead of sickled hemoglobin.
Is Casgevy a cure? It's a functional cure for most patients. The vast majority stop having severe pain crises and no longer need transfusions. But it's not a guarantee, and long-term data are still accumulating.
How much does Casgevy cost? $2.2 million in the US, not including hospitalization or supportive care.
Are there other CRISPR therapies in development? Yes. In vivo therapies for hereditary angioedema, amyloidosis, and cancers are in late-stage trials.
What is the difference between Casgevy and Lyfgenia? Casgevy edits DNA with CRISPR. Lyfgenia adds a gene using a lentiviral vector. Casgevy is approved for two diseases; Lyfgenia for one.
Can CRISPR therapies be given directly to patients? Not yet. All approved CRISPR therapies are ex vivo. In vivo therapies are in trials but not approved.
What are the risks of CRISPR therapy? Off-target editing, conditioning toxicity, and unknown long-term effects.
Who is eligible for Casgevy? Patients 12 and older with severe sickle cell disease or transfusion-dependent beta-thalassemia.
Is CRISPR therapy available for other diseases? Not yet. Trials are ongoing for cancers, amyloidosis, and other genetic disorders.
Stay informed about the latest breakthroughs in gene editing. Subscribe to our newsletter for in-depth analyses and expert insights on CRISPR and other emerging biotechnologies.